Literature DB >> 1581279

Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis.

P J Ryan1, R Harrison, G M Blake, I Fogelman.   

Abstract

OBJECTIVE: To assess compliance with recommendations for hormone replacement therapy (HRT) in postmenopausal women following screening for osteoporosis.
DESIGN: A postal questionnaire sent to women an average of 8 months (range 6-12) following measurement of their bone mineral density (BMD), and recommendations regarding HRT given to the referring general practitioner.
SETTING: Referrals from local general practitioners. Mixed social class.
SUBJECTS: 400 postmenopausal women aged 40-69 years (average age 52). MAIN OUTCOME MEASURES: Compliance with advice and if failing to comply, reasons for not doing so.
RESULTS: Replies were received from 352 women (88%) and 74% of respondents followed advice to start, continue, or refrain from starting or continuing HRT with regard to protecting their skeleton. Those who rejected advice to take HRT mostly had concern over side effects or the efficacy or safety of treatment. Of the women who started HRT 28% subsequently stopped, the principal reasons being withdrawal bleeding and weight gain. Of the women recommended to take HRT, 39% were not taking treatment by 8 months after referral, either because they ignored advice given (22%) or because of side effects (17%).
CONCLUSIONS: Screening leads to increased usage of HRT among women at most risk for osteoporosis. However, almost 40% of women with low bone mineral density were not taking HRT 8 months after referral, and therefore until improved compliance has been demonstrated screening cannot be widely recommended.

Entities:  

Mesh:

Year:  1992        PMID: 1581279     DOI: 10.1111/j.1471-0528.1992.tb13732.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  24 in total

Review 1.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 2.  Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  R H Foster; J A Balfour
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 3.  Alternative treatments for menopausal symptoms. Systematic review of scientific and lay literature.

Authors:  M M Seidl; D E Stewart
Journal:  Can Fam Physician       Date:  1998-06       Impact factor: 3.275

4.  Predictors of compliance with a home-based exercise program added to usual medical care in preventing postmenopausal osteoporosis: an 18-month prospective study.

Authors:  M A Mayoux-Benhamou; C Roux; A Perraud; J Fermanian; H Rahali-Kachlouf; M Revel
Journal:  Osteoporos Int       Date:  2004-07-29       Impact factor: 4.507

5.  Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.

Authors:  S Adami; M C Baroni; M Broggini; L Carratelli; I Caruso; L Gnessi; M Laurenzi; A Lombardi; G Norbiato; S Ortolani
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

6.  Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England.

Authors:  D H Solomon; M T Connelly; C J Rosen; B Dawson-Hughes; D P Kiel; S L Greenspan; E S Leib; M Holick; A H Miguel; J S Finkelstein
Journal:  Osteoporos Int       Date:  2003-03-14       Impact factor: 4.507

7.  Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy.

Authors:  F Griffiths; B Convery
Journal:  Br J Gen Pract       Date:  1995-07       Impact factor: 5.386

Review 8.  Vaginal rings for menopausal symptom relief.

Authors:  Susan A Ballagh
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs.

Authors:  Susan B Jaglal; June Carroll; Gillian Hawker; Warren J McIsaac; Liisa Jaakkimainen; Suzanne M Cadarette; Cathy Cameron; Dave Davis
Journal:  Can Fam Physician       Date:  2003-04       Impact factor: 3.275

10.  What do Norwegian women and men know about osteoporosis?

Authors:  J H Magnus; R M Joakimsen; G K Berntsen; A Tollan; A J Søogaard
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.